Evogene Ltd (EVGN) EPS Estimated At $-0.19

November 14, 2017 - By Marie Mckinney

 Evogene Ltd (EVGN) EPS Estimated At $ 0.19

Wall Street await Evogene Ltd (NASDAQ:EVGN) to release earnings on November, 22 before the open. Analysts forecast EPS of $-0.19, up exactly $0.01 or 5.00 % from 2014’s $-0.2 EPS. After posting $-0.18 EPS for the previous quarter, Evogene Ltd’s analysts now forecast 5.56 % negative EPS growth. It is down 23.47% since November 14, 2016 and is downtrending. It has underperformed by 40.17% the S&P500.

Evogene Ltd. is a biotechnology firm for the improvement of crop productivity. The company has market cap of $98.09 million. The Firm is engaged in developing seed traits for improved yield and abiotic stress tolerance, seed traits for biotic stress resistance, herbicides and bio-stimulants. It currently has negative earnings. The Firm operates a seed business under its subsidiary Evofuel Ltd. (Evofuel).

More important recent Evogene Ltd (NASDAQ:EVGN) news were published by: Globenewswire.com which released: “Evogene Appoints a New Member to Board of Directors and a New Chief Operating …” on August 11, 2016, also Globenewswire.com published article titled: “Evogene Announces Revised and Expanded Market Focus and New Corporate Structure”, Globenewswire.com published: “Evogene to Transfer Stock Exchange Listing to NASDAQ” on December 19, 2016. More interesting news about Evogene Ltd (NASDAQ:EVGN) was released by: Globenewswire.com and their article: “Evogene and ICL Innovation Sign Collaboration for Development of Crop Enhancers” with publication date: February 14, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.